Updates are available Correction dated 2023-05-22

Article History

Accepted: 11 January 2023

First Online: 28 March 2023

Change Date: 22 May 2023

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1038/s41585-023-00783-6

Competing interests

: K.M.R. is a consultant for Urogen Inc. J.J.M. is a consultant for Merck, AstraZeneca, Ferring, Incyte, Janssen, Foundation Medicine, BMS, UroGen, receives research funding from Epizyme, Hope Foundation, VHA, NIH, DoD; receives compensation for talks/educational courses from AUA, OncLive, Olympus, UroToday; clinical trials: SWOG, Genentech, Merck, AstraZeneca, Incyte; has two patents for T1 and TCGA classifier. B.M.F. is on the advisory board of Guardant, Janssen, Gilead, Merck, Immunomedics/Gilead, QED therapeutics; is a consultant for QED therapeutics, Boston gene; has patent royalties for Immunomedics/Gilead; receives honoraria from Urotoday; receives research support from Eli-Lilly. G.P.S. is an advisory board member for BMS, Genentech, EMD Serono, Merck, Sanofi, Seattle Genetics/Astellas, Astrazeneca, Exelixis, Janssen, Bicycle Therapeutics, Pfizer, Gilead, Scholar Rock, G1 Therapeutics, Eli Lilly/Loxo Oncology, Infinity Pharmaceuticals, Lucence Health, IMV; receives research support from Sanofi, Astrazeneca, Gilead, QED, Lucence, Predicine, BMS, EMD Serono, Jazz Therapeutics; is in the steering committee of the following studies: BMS, Bavarian Nordic, Seattle Genetics, QED, G1 Therapeutics (all unpaid), and Astrazeneca, EMD Serono, Debiopharm (paid); is on the data safety monitoring committee of Mereo; his spouse is employed by Myriad; travel costs: BMS, Astrazeneca; had writing/editor fees from Uptodate; is the Editor of Elsevier Practice Update Bladder Cancer Center of Excellence; receives speaking fees from Physicians Education Resource (PER), Onclive, Research to Practice, Medscape, Cancer Network, Masters Lecture Series (MLS). S.P.L. is a consultant/ advisory board member for Aura Bioscience, BMS, C2iGenomics, FerGene, Genentech, Merck, Pfizer/EMD Serono, Stimit, UroGen, Vaxiion, Verity; clinical trials: Endo, FKD, JBL (SWOG), Genentech (SWOG), QED Therapeutics, UroGen, Vaxiion, Viventia; has a patent for TCGA classifier; receives honoraria from Annenberg, Clinical Care Options, Grand Rounds Urology, Ology, UroToday. J.S.R. is an employee and equity holder in Foundation Medicine; is a consultant and equity holder in Tango Therapeutics and Celsius Therapeutics. P.E.S. is the NCCN bladder and penile cancer panel vice chair (leadership position, non-financially incentivized). R.K.J. is an advisory board member for Pfizer; is in the speakers bureau of Astellas/Seattle Genetics. A.M.K. is a consultant for Arquer Diagnostics, Asieris, Biological Dynamics, Bristol Myers Squibb, CG Oncology, H3 Biomedicine/Eisai, Engene, FerGene, Imagin Medical, Janssen, Medac, Merck, Photocure, ProTara, Seattle Genetics, Sessen Bio, Theralase, US Biotest, Urogen Inc, Roche, TMC Innovation; receives grants/research support from Adolor, BMS, FKD Industries, FerGene, Heat Biologics, Merck, Photocure, SWOG, NIH/GU SPORE, AIBCCR, Janssen (+ Taris), Seattle Genetics; has a patent for CyPRIT (Cytokine Predictors of Response to Intravesical Therapy); is a board member of the International Bladder Cancer Group (IBCG). R.L. receives research support from Predicine; Veracyte; CG Oncology; Valar labs; is in the clinical trial protocol committee of CG Oncology; is a scientific advisor/consultant for BMS, Merck, Fergene, Arquer Diagnostics, Urogen Pharma, Lucence, CG Oncology.